Drug
tezosentan
tezosentan is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_3
3
75%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Terminated2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 33 (75.0%)
Trials by Status
terminated250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
Tezosentan in the Treatment of Acute Heart Failure
NCT00524433
completedphase_3
Tezosentan in Acute Heart Failure
NCT00525707
terminatedphase_3
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
NCT00458276
terminatedphase_2
Tezosentan in Pulmonary Arterial Hypertension
NCT01077297
Clinical Trials (4)
Showing 4 of 4 trials
NCT00524433Phase 3
Tezosentan in the Treatment of Acute Heart Failure
NCT00525707Phase 3
Tezosentan in Acute Heart Failure
NCT00458276Phase 3
Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery
NCT01077297Phase 2
Tezosentan in Pulmonary Arterial Hypertension
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4